BioAge Labs vs Regeneron
Side-by-side comparison of AI visibility scores, market position, and capabilities
Clinical-stage biotech targeting metabolic aging for obesity and muscle-wasting disorders. IPO Sep 2024 (Nasdaq: BIOA); $198M raised; lead program azelaprag discontinued; pivoting to NLRP3 inhibitors.
About
BioAge Labs is a clinical-stage biopharmaceutical company that harnesses the biology of human aging to discover novel targets and therapies for metabolic diseases. The company went public on the Nasdaq Global Select Market in September 2024 under the ticker BIOA, raising $198M. Its lead program, azelaprag — an oral APJ agonist — was discontinued in January 2025 after the Phase 2 STRIDES obesity trial observed liver transaminitis in a subset of patients. BioAge has since pivoted its APJ program to next-generation oral and parenteral agonists targeting 2026 IND submissions, while advancing BGE-102, a brain-penetrant NLRP3 inhibitor development candidate with potential best-in-class CNS and metabolic applications. The company continues to leverage its proprietary human aging database to identify and validate novel drug targets.
Tarrytown NY biopharma giant; creator of Dupixent (>$14B revenue), Eylea, and Kevzara. Velocity Genome platform drives fast antibody and bispecific drug discovery.
About
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized mouse technology that dramatically accelerates the discovery of human antibodies—and has used it to produce multiple best-in-class biologics across inflammatory, oncologic, and eye diseases.\n\nRegeneron's commercial portfolio is anchored by Dupixent (dupilumab), developed with Sanofi, which has become one of the best-selling drugs globally with over $14 billion in 2024 revenues, treating atopic dermatitis, asthma, COPD, and other type-2 inflammatory conditions. Additional key products include Eylea (aflibercept) for macular degeneration and PRALUENT for cardiovascular cholesterol lowering. The company's bispecific antibody pipeline, cancer vaccines in collaboration with BioNTech, and gene therapy programs represent its next growth wave.\n\nRegeneron reported over $14 billion in annual revenue in 2024 and maintains a world-class science culture, consistently ranking among the top companies for R&D productivity and employee satisfaction. Its Tarrytown campus houses more than 10,000 employees and remains a leading independent US biopharmaceutical innovator.
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.